Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

Interim analysis of Phase 2 clinical data presented at the 2007

Chemotherapy Foundation Symposium

BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company's third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC. These findings indicate favorable interim results in terms of response rate and survival for Amrubicin in second-line treatment of small-cell lung cancer patients with extensive disease (ED) SCLC. The early results of this study were presented at the 2007 Chemotherapy Foundation Symposium today in New York City.

"Treatment options for second-line SCLC are limited and preliminary data from the US-based Phase 2 sensitive SCLC trial indicate that Amrubicin may provide a new option for SCLC patients who desperately need more treatment choices," said principal investigator Robert M. Jotte, MD, PhD, Medical Director of the Lung Cancer Clinic of the Rockies, Developmental Co-Chair USON Lung Committee. "As we near completion of the Phase 2 trial, we hope that accrual to the Phase 3 trial will be rapid and confirm the results of the US Phase 2 trial and similar trials in Japan."

The trial presented today compares Amrubicin and topotecan in patients with ED-SCLC that initially responded to first-line platinum-based therapy but whose disease recurred or progressed at least 90 days after completion of first-line treatment (sensitive SCLC). Study participants are randomized in a 2:1 ratio to receive either IV Amrubicin (40mg/
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray ... Hydrostatic Weighing) - Global Analysis & Forecast to 2019", ... was pegged at $911.1 Million 2014 and is estimated ... a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Inc.,(Nasdaq: MEDX ) announced today interim ... hormone refractory prostate cancer (HRPC) demonstrating,dose-dependent T-cell ... anti-CTLA-4 antibody. These studies were done in,combination ... that stimulates the proliferation of white blood ...
... GAITHERSBURG, Md., April 15 MedImmune today announced,that ... a potential treatment,for patients with asthma, with the ... (MAb) targeting interleukin-13 (IL-13). One of the,studies is ... Australia designed to,assess the potential of the anti-IL-13 ...
Cached Medicine Technology:Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 2Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 3Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting 4MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 2MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13 3
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... ... ... Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, February ... In the two weeks that separate the conference championships and the Super Bowl, there is ... will mark the 50th time it has been held and the festivities will take place ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... ... 2015 , ... Well-known for its unique pastries and delicious confections, Pastry Palace, ... designs, making life just a little bit sweeter for newlyweds. A family-owned business, the ... orders one. , The bakery provides a full line of custom wedding cakes. Brides ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... use of dexamethasone early in the treatment of children ... childhood cancer, may help reduce the risk of relapse ... conference on Saturday, December 6, at 2:00 p.m., during ... Hematology in San Francisco, CA. Additional research will be ...
... Dec. 6 Purple Cowboy is a new wine that will,help ... National,Finals Rodeo in Las Vegas this month. , ... combination, but in terms of the,professional rodeo community,s commitment to end ... This year, Las Vegas will host the ultimate championship of ...
... Dutch Health Insurance System model, according to an article by ... Journal of Health Politics, Policy and Law . , ... University of Texas School of Public Health at Houston, co-authored ... the Netherlands and its possible lessons for the United States. ...
... many tumors can be left untreated, depending on man,s age ... prostate cancer may prompt an understandable feeling of dread, but ... disposal for tackling the disease, medical experts say. , There ... should be considered strongly when weighing various procedures. In fact, ...
... Dec. 5 Two new studies out this week add to ... associated with increased risk of adverse mental health effects. The two ... and the Journal of Psychiatric Research . Both had ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ...
... understand the connection , , FRIDAY, Dec. 5 (HealthDay News) ... mental health and your respiratory health -- specifically asthma. ... were more likely to have asthma than those who ... report. , If you,re a person with both asthma ...
Cached Medicine News:Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 2Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 3Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 4Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 5Health News:Novel treatments show improvements in survival and response rates for leukemia and lymphoma 6Health News:The Days of Wine and Rodeo 2Health News:UT public health policy expert says US can learn from Dutch universal healthcare coverage 2Health News:Treatment Options Are Many for Prostate Cancer 2Health News:Treatment Options Are Many for Prostate Cancer 3Health News:Poor Mental Health May Boost Asthma Risk 2
... provides a versatile means of sectioning fresh ... The 1000 employs a vibrating blade principle ... The creation of artifacts, the alteration ... and other deleterious effects inherent in freezing ...
... The NEW Vibratome 3000 Deluxe Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
... The Vibratome 1000 Plus Sectioning System ... or fixed, animal, or plant tissues. ... which allows sectioning without freezing or embedding. ... of morphology, the destruction of enzyme activities, ...
Medicine Products: